• Currently leading 4 teams with 35+ scientists for molecular biology and protein sciences.• Leading multiple (Fee For Service) FFS and FTE projects with strict timelines and deliverables for Syngene CRO.• Leading the Sanger sequencing and NGS facility and projects to ensure smooth operations and timely delivery of data.• Working with business development team for proposal writing and cost analysis for FFS projects.

• Led a group of 10 scientists with various scientific skills sets to generate ideas and data for biomaterials.• Developed sustainable biomaterials for food and fuel industry and generate new ideas for innovative bioproducts. • I led biomaterials projects on Advanced Biomaterials Research using synthetic biology. Responsible for research and development, business development and innovation management, from concept to commercialisation.

• Led synthetic biology teams in the Biofuels and Biomaterials projects that developed genetically engineered cyanobacterial strains by different methods for library screening and transformation methods.• Generate new sustainable and patentable biomaterials for food, fuel and cosmetics. • Delivered new genetically modified strains with improved traits for biofuel and biomaterial production and developed new transformation protocols for production strains.

Validation of new products and processes and generation of applications data.• Provided applications data for Promega’s genomics, proteomics, and cellular analysis product lines. Acted as qPCR expert for Promega qPCR products. Supervised and trained the sales team and technical scientists (domestic and international). Supported Promega branches and distributors in Pac‐Asia and India. Assisted with experimental design and trouble‐shooting. Wrote technical manuals and bulletins for Promega products.

•Developed antibody-based universal protein switch platform using antibody alternatives as versatile binding domains by mutant diversity DNA library creation and directed evolution strategies. •Rationally designed and altered binding domain of synthetic antibody for binding to different target molecules. •Constructed unique scheme for periplasmic expression of antibody mimics using different signal sequences.